权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Data mining tool to build database to reduce animal testing in drug development.

数据挖掘工具建立数据库以减少药物开发中的动物试验。

基本信息

批准号：
10042916
负责人：
金额：
$ 6.3万
依托单位：
CONSONEAI LTD
依托单位国家：
英国
项目类别：
Grant for R&D
财政年份：
2022
资助国家：
英国
起止时间：
2022 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=10042916
关键词：
Data mining tool build database

项目摘要

ConsoneAI is biotech business focused on reducing the need for animal testing and developing safer drugs quicker and more effectively by creating an Insilco software to predict toxicological values for new chemicals being considered for human therapeutic effect, ie new Drugs.Our Platform is called DioScor and will predict toxicology value and physiological affects which are essential in the evaluation of new drugs by looking at the poisoning (Toxic) effect of the chemical structure. Currently a large number of animals are tested to ensure these toxic effects are not dangerous to human health before the first clinical trials in human studies take place. The DioScor prediction will aim to reduce the number of animal testing experiments by allowing the user to see the predicted toxicological effects of a drug across a range of animal species through to human allowing the pharmaceutical company's drug development and clinical development to select the most effective animal study and drug molecules.The drug development process can be a difficult and long process with approximately 92% of all new drugs failing to make it to market. This has a huge financial cost and has a considerable impact on the volume and numbers of animal testing. The drug development process must use the animal testing to provide safety data before new molecules are used for human trial. DioScor will look at the toxicological impact at each stage of the development process and evaluate the effect on the animal species and how it will translate between animal species. The translation of tox data between animals equates to approx. 46% of drugs will fail. DioScor prediction will reduce the number of these animal testing studies to focus pharmaceutical resources to those molecules which show the best translational data between species.Our business goal is work with the pharmaceutical industry and regulators to provide safe evidence to develop animal and clinical trials and ultimately create drugs to market more effectively.

ConsoneAI是一家生物技术公司，专注于减少对动物试验的需求，并通过创建Insilco软件来更快更有效地开发更安全的药物，以预测正在考虑用于人类治疗效果的新化学品的毒理学值，即新药。我们的平台被称为DioScor，将通过观察毒性（毒性）来预测毒理学价值和生理影响，这在新药评估中至关重要。化学结构的影响。目前，在进行第一次人体临床试验之前，对大量动物进行了测试，以确保这些毒性作用不会对人类健康造成危险。DioScor预测的目标是通过允许用户看到药物在一系列动物物种到人类之间的预测毒理学效应来减少动物测试实验的数量，从而允许制药公司的药物开发和临床开发选择最有效的动物研究和药物分子。所有未能上市的新药这会产生巨大的经济成本，并对动物测试的数量和数量产生相当大的影响。药物开发过程必须在新分子用于人体试验之前使用动物试验来提供安全性数据。DioScor将研究开发过程中每个阶段的毒理学影响，并评估对动物物种的影响以及如何在动物物种之间转化。动物之间的毒性数据转换约等于。46%的药物会失败。DioScor的预测将减少这些动物试验研究的数量，将制药资源集中到那些显示物种间最佳翻译数据的分子上。我们的业务目标是与制药行业和监管机构合作，为开发动物和临床试验提供安全的证据，最终更有效地创造药物推向市场。